logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Buyout Speculation Boosts This Biotechnology Stock

By  +Follow June 11, 2014 8:05AM
Share:
Tickers Mentioned:

While equity markets edged lower Tuesday, one small cap stock in the biotechnology sector surged, extending its gains from previous trading sessions. Shares of Achillion Pharmaceuticals Inc. (ACHN) , a biopharmaceutical company focused on the development and commercialization of treatment for infectious diseases, have surged in early trading on Tuesday on ongoing buyout speculation.

Stock Continues to Gain Momentum

After surging more than 47% in Monday’s trading session, shares of Achillion Pharmaceuticals gained another 83% on Tuesday to close at $7.79. The trading volume of 27.15 million is more than 10 times the daily average volume of 2.66 million. With the entire trading day still left, Achillion shares could see a significant spike in volume.

Achillion Pharmaceuticals shares have now gained more than 170% in the last three trading sessions. Despite the surge, the stock is still trading below its 52-week high of $8.49. However, the surge has pushed the small cap stock above its 50-day and 200-day moving averages. The stock’s MACD has also crossed the signal line and the zero-line, which is a strong bullish signal.

Buyout Rumors Spark Rally

The rally in Achillion Pharmaceuticals shares has been sparked by rumors of a takeover. The takeover speculation began after Merck (MRK) announced the acquisition of the company’s rival Idenix Pharmaceuticals Inc. (IDIX) .

Achillion Pharmaceuticals shares have got a further boost following news that the U.S. FDA has allowed the company to conduct trials in patients with hepatitis C.

Milind Deshpande, Ph.D., President and CEO of Achillion Pharmaceuticals, noted that the company remains focused on developing regimens using ACH-3422 and ACH-3102, its second-generation Phase 2 NS5A inhibitor. Deshpande added that the second half of 2014 will feature multiple milestones in that program. 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

				
				
By  +Follow June 11, 2014 8:05AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.